Ironwood Pharmaceuticals

Ironwood Pharmaceuticals

Company: Ironwood Pharmaceuticals, Inc. Headquarters: Boston, Massachusetts, USA Founded: 1998 (as Microbia, renamed 2008) Ticker: IRWD (NASDAQ) Employees: ~350 Market Cap: ~$1.5B (2024)

Overview

Ironwood Pharmaceuticals

Company: Ironwood Pharmaceuticals, Inc. Headquarters: Boston, Massachusetts, USA Founded: 1998 (as Microbia, renamed 2008) Ticker: IRWD (NASDAQ) Employees: ~350 Market Cap: ~$1.5B (2024)

Overview

Ironwood Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for gastrointestinal (GI) disorders. The company is best known for [Linzess (linaclotide) for irritable bowel syndrome with constipation and chronic idiopathic constipation](/therapeutics/linaclotide), a guanylate cyclase-C (GC-C) agonist that has become a leading prescription therapy["@ironwood-corp"].

Ironwood's GI focus has significant relevance for [Parkinson's disease](/diseases/parkinsons-disease) patients, who experience among the highest rates of constipation of any patient population. The company's research into GC-C biology and GI motility mechanisms positions it to address autonomic-related GI dysfunction that affects 60-80% of PD patients["@pd-gi-review"].

Technology Platform

Guanylate Cyclase-C (GC-C) Agonist Mechanism

Ironwood's core technology revolves around GC-C receptor agonism:

Mechanism of Action:

• Linaclotide binds to the GC-C receptor on the luminal surface of intestinal epithelial cells
• Activation increases intracellular cyclic GMP (cGMP) levels
• cGMP leads to: (1) accelerated GI transit, (2) increased intestinal fluid secretion, (3) reduced visceral sensitivity
• Minimal systemic absorption (acts locally in the GI tract)

• Restores natural bowel motility without colonic irritation
• Reduces abdominal pain through visceral analgesic effects
• Non-addictive, non-osmotic mechanism (unlike stimulant laxatives)

Relevance to Parkinson's Disease

Patients with [Parkinson's disease](/diseases/parkinsons-disease) suffer from constipation through multiple mechanisms:

Linaclotide addresses the transit and secretion components, making it a targeted therapy for PD-associated slow-transit constipation. Unlike stimulant laxatives, linaclotide does not cause colonic inflammation and can be used chronically without the risk of laxative-induced colonic damage.

Product Portfolio

Linzess (Linaclotide)

| Attribute | Details |
|-----------|---------|
| Brand Name | Linzess |
| Generic Name | Linaclotide |
| Formulation | Oral capsules (72 mcg, 145 mcg) |
| Indication | IBS-C, Chronic Idiopathic Constipation |
| Dosing | Once daily on empty stomach, 30 min before first meal |
| FDA Approval | August 2012 (IBS-C), September 2012 (CIC) |
| Partner | AbbVie (formerly Forest Laboratories) for US commercialization |
| Revenue | >$1B annually (combined with Constella outside US) |

Efficacy:

• 12-18% improvement in spontaneous bowel movement (SBM) frequency vs. placebo
• Significant reduction in abdominal pain scores
• Onset of action within 1-2 weeks of consistent dosing

• Diarrhea (most common, ~20%)
• Abdominal pain
• Flatulence
• Minimal systemic absorption limits systemic side effects

Constella (Linaclotide, ex-US)

marketed as Constella outside the United States through AbbVie/partners, covering EU, Canada, and other markets.

Clinical Development

PD-Specific Research and Observations

While not specifically developed for PD, linaclotide has been evaluated in context of PD-associated constipation:

• Observational studies: PD patients with constipation treated with linaclotide showed improved bowel frequency and reduced constipation severity
• Mechanism fit: Addresses slow-transit component of PD constipation
• Levodopa absorption consideration: By improving GI transit, linaclotide may stabilize levodopa absorption and reduce motor fluctuation variability associated with constipation

Other Pipeline Programs

| Program | Indication | Mechanism | Status |
|---------|------------|-----------|--------|
| IW-3300 | Functional GI disorders | GC-C agonist (novel formulation) | Preclinical |
| CNP analogs | Various GI targets | Guanylate cyclase modulation | Discovery |

Strategic Partnerships

AbbVie Collaboration

Ironwood partnered with AbbVie (formerly Forest Laboratories) for US commercialization of linaclotide:

• AbbVie handles sales, marketing, and distribution
• Ironwood retains manufacturing and receives royalties
• Collaboration extended through 2030+

Global Expansion

• EU/Canada: Constella marketed by multiple partners
• Japan: Partnered with Astellas for development and commercialization
• Other markets: Various regional partnerships

Related Pages

Disease and Mechanism Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Autonomic Dysfunction in Parkinson's Disease](/mechanisms/parkinsons-autonomic-dysfunction)
• [Gut-Brain Axis in Alpha-Synuclein Propagation](/mechanisms/gut-first-brain-first-alpha-synuclein-propagation)
• [Enteric Nervous System](/entities/enteric-nervous-system)

Treatment Pages

• [Linaclotide (Linzess) Therapeutic Profile](/therapeutics/linaclotide)
• [PD Gastrointestinal Dysfunction Treatments](/therapeutics/pd-gastrointestinal-dysfunction)
• [Parkinson's Non-Motor Symptom Treatments](/therapeutics/parkinsons-non-motor-symptoms)

Company Pages

• [Astellas Pharma](/companies/astellas-pharma) (linaclotide Japan partner)
• [PD Autonomic Dysfunction Treatment Companies](/companies/pd-autonomic-dysfunction-treatments)

References